Follistatin-like 1 (FSTL1) is a prognostic biomarker and correlated with immune cell infiltration in gastric cancer

Li Li
First Affiliated Hospital of Nanchang University

Shanshan Huang
First Affiliated Hospital of Nanchang University

Yangyang Yao
First Affiliated Hospital of Nanchang University

Jun Chen
First Affiliated Hospital of Nanchang University

Junhe Li
First Affiliated Hospital of Nanchang University

Xiaojun Xiang
First Affiliated Hospital of Nanchang University

Jun Deng (✉ dengjun19871106@ncu.edu.cn)
First Affiliated Hospital of Nanchang University

Jianping Xiong
First Affiliated Hospital of Nanchang University

Research

Keywords: FSTL1, tumor immune infiltrates, prognostic biomarker, gastric cancer

DOI: https://doi.org/10.21203/rs.3.rs-60171/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: Follistatin-like 1 (FSTL1) plays a central role in the progression of tumor and tumor immunity. However, the effect of FSTL1 on the prognosis and immune infiltration of gastric cancer (GC) remains to be elucidated.

Methods: The expression of FSTL1 data was analyzed in Oncomine and TIMER databases. Analyses of clinical parameters and survival data were conducted by Kaplan-Meier plotter and immunohistochemistry. Western blot assay and real-time quantitative PCR (RT-qPCR) was using to analyzed protein and mRNA expression, respectively. The correlations between FSTL1 and cancer immune infiltrates was analyzed by Tumor Immune Estimation Resource (TIME), Gene Expression Profiling Interactive Analysis (GEPIA) and LinkedOmics database.

Results: The expression of FSTL1 was significantly higher in GC tissues than in normal tissues, and bioinformatic analysis and Immunohistochemistry (IHC) indicated that high FSTL1 expression significantly correlated with poor prognosis in GC. Moreover, FSTL1 was predicted as an independent prognostic factor in GC patients. Bioinformatics analysis results suggested that FSTL1 mainly involved in tumor progression and tumor immunity. And significant correlations were found between FSTL1 expression and immune cell infiltration in GC.

Conclusions: The study effectively revealed useful information about FSTL1 expression, prognostic values, potential functional networks and impact of tumor immune infiltration in GC. In summary, FSTL1 can be used as a biomarker for prognosis and evaluating immune cell infiltration in GC.

1. Background

Gastric cancer (GC) is the fourth most common cancer worldwide, despite the rapid development of diagnosis and therapies, GC is still one of the most leading cause of death [1]. Thus, it is urgent to investigate the mechanism of cancer progression, as well as explore the potential biomarkers of diagnosis, prognosis, and therapy in GC. In recent years, immunotherapy has rapidly developed into a promising and effective therapeutic strategy for GC patients [2]; however, the molecular mechanisms related to immune dysfunction remain unknown. Several studies have uncovered significant correlations between tumor microenvironment (TME) and the mechanisms of immune dysfunction[3-5]. Tumor-infiltrating lymphocytes (TILs), including tumor-associated macrophages (TAMs) and tumor-infiltrating neutrophils (TINs), display unique histological features that can distinguish the differentiation of malignancies and often vary between individual patients. In addition, TILs have been proven to play essential roles in the prognosis and treatment of malignancies [6-9]. Hence, it is important to clarify the immunophenotype of tumor-immune interactions, as this will lead to the identification of novel immunotherapeutic-related targets in various malignancies.

Follistatin-like 1 (FSTL1) is a transmembrane extracellular glycoprotein of the secreted protein acid and belongs to the BM-40/SPARC/osteonectin family. FSTL1 was first cloned in 1988 from the synovial
tissues of patients with rheumatoid arthritis after it was detected in the serum and synovial fluid of patients with the disease [10]. Immunological studies suggest that FSTL1 regulates joint inflammation in arthritic diseases, while also modulating allograft tolerance. In addition, FSTL1 acts as an autoantigen in patients with rheumatoid arthritis by inhibiting IL6 and producing IL17 to play cardioprotective roles in several cardiovascular diseases [10, 11]. In previous reports, FSTL1 has been shown to produce varying effects in terms of tumors progression and inhibition. For example, FSTL1 has been found to promote tumor inhibition in breast cancer [12] and clear-cell renal cell carcinoma [13]; however, it is a poor prognostic indicator of colorectal cancer [14], esophageal squamous cell carcinoma [15], and hepatocellular carcinoma [16]. FSTL1 also affects the progression of multiple tumors by modulating the host immune system, leading to immune dysfunction in many cases. FSTL1-induced immune dysfunction leads to tumor bone metastases [17] and activation of immune evasion mechanisms in patients with non-small cell lung cancer (NSCLC) through the FSTL1-DIP2A axis [18]. FSTL1 plays a crucial role in tumor-immune and cancer cell progression. However, the effects of FSTL1 on GC prognosis and immune infiltration are still unclear. The potential functions and mechanisms of FSTL1 in cancer progression and immunology need be discovered.

In this study, we investigated the expression of FSTL1 in GC using bioinformatics analysis, as well as clinical samples, and analyzed the association of FSTL1 expression with different TILs in TME using the TIMER database and CIBERSORT method. The results demonstrate that FSTL1 holds prognostic value, and explain the potential mechanism and impact of FSTL1 and TME in GC.

2. Materials And Methods

2.1 Bioinformatical analysis

FSTL1 mRNA expression was assessed in GC using Oncomine V.4.5 (www.oncomine.org), GEPIA (http://gepia.cancer-pku.cn/index.html) and TIMER database (https://cistrome.shinyapps.io/timer/) [19-21]. The correlation between FSTL1 expression and survival in GC were analyzed with the Kaplan-Meier plotter [22]. TIMER database was used to investigate FSTL1 expression in multiple cancers and the correction between FSTL1 expression and TME in GC [23, 20]. The GSVA package of R language was used to detect activity changes of immune-related pathway after FSTL1 expression changes [24], and the sources of immune-related pathway were used in Molecular Signatures Database (http://software.broadinstitute.org/gsea/msigdb) [25]. Median FSTL1 expression level of tumors from The Cancer Genome Atlas (TCGA) database (https://cancergenome.nih.gov) was grouped into high and low expression groups. Immune-related pathway predictions in different levels of FSTL1 expression were performed using immune-related signatures. The screening criteria were \( p \)-value < 0.01 and false discovery rate (FDR) < 0.01. For the prediction of tumor infiltrating lymphocytes (TILs), the expression matrices were uploaded to CIBERSORT (https://cibersort.stanford.edu/) [26]. The valid samples were selected using \( p \)-value < 0.05. Both Gene Ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed utilizing the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.8[27, 28].
2.2 Patients and tissue specimens

All the clinical GC samples were obtained from the First Affiliated Hospital of Nanchang University. Formalin-fixed, paraffin-embedded samples from 240 GC patients were collected from January 2011 to October 2012, and 50 fresh GC tissues and paired adjacent noncancerous tissues were stored in liquid nitrogen before use. Before the operation, the patients had not accepted chemotherapy, radiotherapy or other treatments. All samples were collected with the consent of the patient, and the study was approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University. All patient specimens and clinical data involved in this study complied with the Declaration of Helsinki.

2.3 RNA extraction and real-time quantitative PCR

Total RNA from GC fresh tissues was extracted by TRIzol reagent (Invitrogen, USA) and reverse transcribed by EasyScript First-Strand cDNA Synthesis SuperMix Kit (TransGen Biotech, China). RT-qPCR was evaluated by the StepOnePlus Real-Time PCR System (Applied Biosystems, USA) and Fast Start Universal SYBR Green Master Mix (Takara, Japan). The relative expression of FSTL1, forward (5'-GCCATGACCTGTGACGGAAA -3'); reverse (5'-CAGCGCTGAAGTGGAGAAGA -3') relative to the internal control (GAPDH) was analyzed using the 2−ΔΔCT method.

2.4 Western blot

The total protein was extracted with RIPA buffer containing protease inhibitor cocktail, separated with 10% SDS-PAGE gel and transferred to polyvinylidene difluoride membrane (Bio-Rad Laboratories, USA). And the membranes were blocked by 10% milk solution for 1 hour at room temperature following incubated with primary antibodies against FSTL1 (1:1000, DF12274, Affinity, China) and β-actin (1:1000; #4970; Cell Signaling Technology, USA) for overnight at 4℃. Then the membranes were washed 3 times in Tri-buffered saline with Tween-20, and incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (Anti-rabbit IgG, #7074 Cell Signaling Technology, USA) for 1h at room temperature. After washed 3 times in Tri-buffered saline with Tween-20, the signals were detected with super sensitive regent (Thermo Fisher Scientific, USA).

2.5 Immunohistochemistry

Formalin-fixed paraffin-embedded tissues sections (4-μm) were degreased in xylene and rehydrated in different concentrations of alcohol and distilled water before antigen retrieval. The sections were blocked in 3% H₂O₂ at room temperature for 5-10 minutes to eliminate endogenous peroxidase activity. Then sections were incubated with anti-FSTL1 antibody (1:100, DF12274, Affinity, China) at 4℃ overnight. The slides were washed 2 times in PBS for 5 minutes each time and incubated with secondary antibodies for 40 minutes at room temperature, then washed 3 times in PBS. 3,3'-diaminobenzidine and hematoxylin were used to color these slides. FSTL1 expression level was scored according to the proportion of stained tumor cells and the intensity of the staining[29]. The staining intensity was scored as: 0 (negative), 1 (weak), 2 (moderate) and 3 (strong). The proportion of staining was scored as: 0 (0–5%); 1 (5–25%); 2
(25–50%); 3 (50–75%) and 4 (75–100%). The final FSTL1 expression scores were calculated by multiplying the above two scores. Slides were considered as low or high expression, with final scores of ≤6 or >6, respectively. Two independent pathologists who were blinded to observed the results under an optical microscope.

2.6 Statistical analysis

The survival curves of Kaplan-Meier plots and GEPIA databases were displayed by HR with p-values or Cox p-values from the log-rank test. Gene expression distribution from the TIMER database was displayed using box plots, with statistical significance assessed by the Wilcoxon test, and the correlation of gene expression from the TIMER databases was evaluated with Spearman's correlation coefficient and estimated using statistical significance. Kaplan-Meier method and log-rank test were used to analyzed overall survival curves. Differences in the mRNA expression levels of FSTL1 in fresh GC and matched normal tissues were analyzed using paired t-tests. Univariate and multivariate Cox's proportional hazard models were conducted to analyzed the value of each clinic parameter for predicting overall survival. Statistical significance was defined as p<0.05.

3 Results

3.1 FSTL1 expression and potential prognosis in GC

TIMER and Oncomine databases were used to assess the differential expression of FSTL1 based on cancer type. The majority of data sets from the TIMER and Oncomine database showed that FSTL1 was highly expressed in most malignancies, especially in GC (Figure 1A, B). In representative Chen Gastric data sets (N=35) from the Oncomine database[30], FSTL1 expression was significantly high expression in GC tissues compared with normal tissues, and was elevated in multiple pathological typing, including adenocarcinoma, intestinal carcinoma, diffuse carcinoma and mixed carcinoma (Figure 1C, D). Same result was confirmed in GEPIA database, and the expression of FSTL1 increases with the stage of GC (Figure 1E, F). In addition, we further confirmed that FSTL1 was highly expressed in GC through RT-qPCR and Western blot (Figure 2A, F). Moreover, the mRNA expression of FSTL1 in the Nx group (P=0.037) and stage III group (P=0.018) was significantly higher than N0 group and the I/II group in GC patients, respectively (Figure 2C, D). But there was no significant change in FSTL1 expression in stage T grouping and differentiation grouping (Figure 2B, E).

Meanwhile, KM-plotter and GEPIA database survival analysis indicated that highly FSTL1 expression indicated poorly prognosis in GC patients (Supplementary Figure 1A, B). To confirm the predicted prognostic value of FSTL1 in GC, FSTL1 were analyzed in random selected 240 primary GC tissues and paired adjacent non-tumor tissues by immunohistochemistry. The staining of FSTL1 protein ranged from weak to strong (Figure 2H), and the result showed that FSTL1 positive staining was increased in GC tissues than adjacent non-tumor tissues (Figure 2I). The positive expression rate of FSTL1 (43.3%, 104/240) in GC samples was significantly higher than that in adjacent non-tumor tissues (15%, 36/240) (P<0.001) (Figure 2G).
Kaplan-Meier analysis and log-rank test were performed to analyzed the prognostic value of FSTL1 expression in GC patients. The result showed that patients with positive FSTL1 expression (41.1±3.8 month) had worse overall survival than negative FSTL1 expression (70.9±3.1 month) (P<0.001) (Figure 2J).

3.2 Correlation of FSTL1 expression and clinical prognosis in GC with different clinicopathological features

To further understand the effect of FSTL1 in the prognosis of GC, we studied the relationship between FSTL1 expression and the clinicopathological features of these cancers using the Kaplan-Meier plotter database and immunohistochemistry assay.

In Kaplan-Meier plotter database, the expression of FSTL1 has a significant correlation with the prognosis of GC patients with various clinicopathological characteristics. It is worth noting that increased FSTL1 expression was associated with worse OS and PFS in stage III-IV and stage N1-3, but not in stage I/II and stage N0 GC patients (Table 1). The result means that FSTL1 expression level can impact the prognosis in the advanced and lymph node metastasis GC patients, which consistent with the increased expression of FSTL1 in III group and Nx group compared with I/II group and N0 group in Figure 2C, D.

Next, correlation between FSTL1 expression and clinicopathological was been investigated (Table 2). The result showed that expression level of FSTL1 was correlated with tumor size (P<0.001), lymph node metastasis (P<0.001), and tumor-node-metastasis (TNM) stage (P=0.001). No significant correlations between FSTL1 expression and ages (P=0.48), gender (P=0.519), depth of invasion (P=0.147), differentiation (P=0.151), nerve invasion (P=0.809) and vascular invasion (P=0.317) were detected. The results are consistent with the results in the KM-Plotter database.

Univariate and multivariate analyses were conducted to investigate the independent prognostic factors of GC patients (Table 3). Univariate analysis indicated that tumor size (P<0.001), depth of invasion (P=0.001), lymph node metastasis (P=0.001), TNM stage (P=0.001), vascular invasion (P=0.003) and FSTL1 expression (P=0.001) was significantly correlated with OS of GC patients. These factors were subjected to multivariate analysis, which indicated that tumor size (P=0.006), depth of invasion (P=0.007), lymph node metastasis (P<0.001), TNM stage (P=0.001) and FSTL1 expression (P=0.002) were independent prognostic factors in GC patients.

3.3 Protein-protein interaction of FSTL1 network analysis

Genes co-expressed with FSTL1 were analyzed by LinkedOmics database, which analyzed mRNA sequencing data of 415 GC patients from TCGA. All the genes associated with FSTL1 GC was showed in Figure 3A. And Figure 3B revealed the most 50 significant genes positively correlated with FSTL1 in GC. The 50 genes differentially expressed associated with highly FSTL1 expression were primarily enriched in extracellular region/exosome/space/matrix/matrix organization, cell adhesion (Figure 3C). KEGG pathway analysis found enrichment in Pathway in cancer, Focal adhesion, PI3K-Akt signaling pathway,
ECM-receptor interaction, which indicated that elevation of FSTL1 was significantly correlated with tumor development and immune response (Figure 3D).

In addition, we applied GSVA and clustering on a set of immune-specific signatures to further validate the enrichment of FSTL1 expression in the immune-related pathway. As FSTL1 expression increased, most immune-related pathways were activated in GC, CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION, INNATE_IMMUNE_SYSTEM, NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY, and others in STAD (Figure 4). Hence, FSTL1 plays a crucial role in immune cell infiltration and tumor-immune system interactions in GC.

### 3.4 Correlation between FSTL1 and tumor environment in GC

TILs, which are essential components of the TME, have been shown to reflect the host antitumor immune response and are prognostic factors for cancer [31, 32]. As mentioned, GO analysis revealed that FSTL1 has functions associated with extracellular region/exosome/space/matrix/matrix organization, cell adhesion, while KEGG analysis indicated that FSTL1 involved in the ECM-receptor interaction pathway, PI3K-Akt signaling pathway. It is well-known that remodeling the extracellular matrix (ECM), disordered PI3K-Akt signaling pathway can exert a great influence on the TME [33, 34]. Thus, we analyzed the correlation between FSTL1 expression and TILs in GC using the TIMER database. The result showed that FSTL1 expression was found to be correlated with high immune infiltration of CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells in GC (Figure 5).

Immune cells are frequently identified based on the expression of cell surface receptors and intracellular markers. To further assess the relationship between FSTL1 and each tumor-infiltrating immune cell, we analyzed the correlation between FSTL1 expression and immune infiltrating cells, including CD8+ T cells, T cells (general), B cells, neutrophils, NK cells and dendritic cells (DCs), monocytes, TAMs, and M1/M2 macrophages, in GC using the TIMER and GEPIA databases. In addition, the functional T cells were also been investigated, including T helper type 1 (Th1), Th2, Th17, follicular helper T cell (Tfh), and regulatory T (Treg) cells, as well as exhausted T cells. Even if the correlation was adjusted based on tumor purity, the majority of tumor-infiltrating immune cell markers were positively correlated with FSTL1 expression in GC (Table 4).

### 3.5 Correlation between FSTL1 expression and macrophage polarization in GC

Studies have shown that polarization from the antitumor M1 (classically activated) macrophage to protumor M2 (alternatively activated) macrophage phenotype is correlated with tumor development [35, 36]. Interesting, we found that the markers for monocytes, TAMs, and M2 macrophages showed moderate-to-strong correlations with FSTL1 expression, while the M1 macrophage markers were weakly correlated with FSTL1 expression (Figure 6A-D, Table 4). To confirm the results with the TIMER database, the correlation between FSTL1 expression and the cell markers for monocytes, TAMs, M1 macrophages, and M2 macrophages in GC was assessed using GEPIA database. Findings from the GEPIA database were consistent with the TIMER database (Supplementary Table 1). Therefore, we using CIBERSORT
method to further explored whether FSTL1 expression was correlated with the polarization of macrophages in GC. The results showed that high FSTL1 expression had a higher ratio of M2 macrophage (Figure 6E-G).

4 Discussion

In this study, we found that: (1) FSTL1 was highly expressed and correlated with worse prognosis in GC patients; (2) High expression of FSTL1 was positive correlated with immune infiltration in GC; (3) High expression of FSTL1 promotes the polarization of M1 macrophages to M2 macrophages in GC.

Studies have showed that FSTL1 was involved in tumor develop and tumor immunity by variety of mechanisms, such as promotes metastasis and chemoresistance through NFκB-BMP signaling pathway in esophageal squamous cell carcinoma[15], activating the focal adhesion signaling pathway to promotes colorectal cancer[14], causing immune dysfunction in lung cancer[18] and tumor with bone metastasis [37]. From these results, we can speculate that FSTL1 is crucially involved in tumor progression and tumor immunity.

In the present study, we found that FSTL1 expression is up-regulated and indicated worse prognosis in GC using bioinformatics. And the results were confirmed by RT-qPCR, western blot and IHC assay. Moreover, the results indicated that highly expression level of FSTL1 was correlated with tumor size, lymph node metastasis and TNM stage, especially. The univariate and multivariate analysis of GC patients suggested that FSTL1 was an independent factor of prognosis in GC. All of the results suggested that FSTL1 may become a potential prognosis predictor in GC patients. To investigate the underlying mechanism, GO and KEGG analyses were performed in DAVID website. Co-expression genes of FSTL1 were enriched in extracellular region/exosome/space/matrix/matrix organization, cell adhesion, and Pathway in cancer, Focal adhesion, PI3K-Akt signaling pathway, ECM-receptor interaction, which have been proved correlated with tumor development and tumor immunity. Thus, we further investigated the relationship between FSTL1 expression and tumor immunity.

TME, which constitutes an important part of tumor immunity, is a complex environment containing a mixture of nutrients, chemokines, immune cells, and other critical non-cancerous components [38]. The interaction between tumor cells and TME plays a crucial role in tumor growth, progression, chemotherapy, and radiotherapy resistance [39-41]. Importantly, tumor-infiltrating immune cells have been found to play roles tumor growth, invasion, and metastasis in various forms of cancer [42]. Another important aspect of this research is the close connection between FSTL1 expression and tumor-infiltrating immune cells in GC. The result from the GSVA analysis and TIMER database suggest that FSTL1 expression is closely related to immune-related pathways and significantly correlated with CD8+ T cell, CD4+ T cell, macrophages, neutrophils, and DCs in GC (Figure 4, 5). Hence, high FSTL1 expression can cause a substantial increase in immune cell tumor infiltration.

Existing research has shown that TAMs, which differentiated from peripheral monocytes, are infiltrating around tumor cells. TAMs secrete a variety of cytokines, which play an important role in tumor
occurrence, metastasis and invasion, under the stimulus of TME. According to the different activation status and function, macrophages can be divided into M1 (classically activated macrophages) macrophage and M2 (alternatively activated macrophages) macrophage. M1 macrophages secrete pro-inflammatory cytokines and chemokines, and present antigens on a full-time basis, participate in the positive immune response, and perform the function of immune surveillance; M2 macrophages have only weak antigen presentation ability and secrete inhibitory cytokines such as IL-10 or TGF-β down-regulate the immune response and play an important role in immune regulation[43, 44]. It’s well known that polarization from the antitumor M1 (classically activated) macrophage to protumor M2 (alternatively activated) macrophage phenotype is correlated with tumor development, and the proportion of M1 and M2 macrophages in TAM is close related to the prognosis of tumor. The large number differentiation of M2 macrophage is correlated with worse prognosis, suggesting that the differentiation of macrophages has important guiding significance for the clinical treatment of tumor[45, 46, 36]. To further investigate the relationship between FSTL1 and tumor-infiltrating cells, we analyzed the connection between FSTL1 expression and tumor-infiltrating cell markers. First, we found that FSTL1 expression is significantly correlated with surface markers of monocytes (CD86, CD115), TAMs (CCL2, CD68, IL10), M1 macrophages (INOS, IRF5, COX2), and M2 macrophages (CD163, VSIG4, MS4A4A) (Figure 6A-D, Table 4, Supplementary Table 1). This indicates that FSTL1 may play an important role in macrophage polarization and affect the progression of GC through macrophage polarization.

In terms of TILs, helper T lymphocytes, including Th1 cells, Th2 cells, Tfh cells, Th17 cells, and Treg cells, are considered to be the major players in tumor immunity[47-49]. The surface marker of helper T lymphocytes (Th1 cells, Th2 cells, Tfh cells, Th17 cells, and Treg cells) show significant correlations with FSTL1 expression (Table 4). Hence, FSTL1 plays a vital role in regulating the potential mechanisms of T cell function in GC. A previous study suggested that high T-bet expression was previously correlated with better DFS and OS in GC patients [50]. Interestingly, FSTL1 expression is positively correlated with T-bet in GC. This indicates that FSTL1 may affect the prognosis of GC by impacting the expression of T-bet. Treg cells have been reported to stimulate GC progression by secreting TGF-β to help the cancer cells escape immune system recognition, and high levels of TGF-β in the TME further stimulate the differentiation and expansion of Treg cells [51, 52]. Previous studies have suggested that Treg cells may be involved in the development and progression of bladder carcinomas and GC [53, 54]. Our results agree that FSTL1 expression is a positive biomarker for Treg cells, including TGF-β in GC. Hence, Treg cells play an essential role in the survival of patients with GC affected by FSTL1.

Furthermore, our results showed that FSTL1 expression is positively related to the infiltration level of DCs and the markers of DCs in GC (Figure 5, Table 4), which indicated that FSTL1 has strong correlation with DCs infiltration in GC. However, the effects of tumor-infiltrating DCs in GC remains unclear. Additional studies are needed to determine how FSTL1 regulates DCs in GC.

Significant correlations have also been detected between FSTL1 and T cell exhaustion markers in GC (Table 4). Previous studies reported that Treg cells could reversibly inhibit the cytotoxic T cell function of attacking tumor cells [55]. On the other hand, exhausted T cells co-express a wide range of surface
inhibitory molecules, such as PD-1, CTLA4, LAG3, and TIM-3 [56]. In general, the higher the number of inhibitory receptors co-expressed by exhausted T cells, the more severe the T cells exhaustion. Although the expression of a single inhibitory receptor does not indicate T cells exhaustion, the co-expression of several inhibitory receptors is an important feature [57, 58]. From our results, the inhibitory receptors, including PD-1, CTLA4, LAG3, and TIM-3, increased in GC with FSTL1 overexpression (Table 4), suggesting that FSTL1 plays a crucial role in the regulation of T cell exhaustion. Hence, FSTL1 is closely correlated with tumor-infiltrating immune cells and indicates that FSTL1 plays a vital role in the immune escape mechanism in patients with GC. Recently, FSTL1 neutralizing antibodies were developed and found to display excellent efficacy in vitro [59]. Also, CTLA4, PD-1, and programmed death ligand-1 (PD-L1) inhibitors have shown promising results in lung cancer, yet the response was unclear in advanced-stage GC [60, 61]. The combined use of FSTL1 neutralizing antibodies with anti-CTLA-4 or anti-PD-1/PD-L1 inhibitors may produce additive or synergistic effects, thus creating a new treatment option. Of course, part of these results haven't been proved or confirmed in our specimens, and further investigation should be conducted in the future.

5 Conclusions

In summary, FSTL1 is commonly expressed and possesses significant prognostic value in GC. High FSTL1 expression is associated with high infiltration levels of CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and DCs in GC, and potentially contributes to the regulation of TAMs, DCs, helper T lymphocytes, and T cell exhaustion. Furthermore, high expression of FSTL1 promotes the polarization of M1 macrophages to M2 macrophages in GC, which may be one of the reasons for the poor prognosis of FSTL1 in GC patients. For these reasons, FSTL1 might be a promising prognostic biomarker for cancer and could provide new ideas for improving tumor immune evasion and immunotherapy in GC.

Abbreviations

FSTL1, follistatin-like 1; GC, gastric cancer; TIMER, Tumor Immune Estimation Resource; RT-qPCR, real-time quantitative PCR; GEPIA, Gene Expression Profiling Interactive Analysis; IHC, immunohistochemistry; DCs, dendritic cells; TME, tumor microenvironment; TILs, tumor-infiltrating lymphocytes; TINs, tumor-infiltrating neutrophils; TCGA, The Cancer Genome Atlas; KEGG, Kyoto Encyclopedia of Genes and Genomes; DAVID, Database for Annotation, Visualization and Integrated Discovery; TNM, tumor-node-metastasis; ACC, Adrenocortical carcinoma; BLCA, Bladder Urothelial Carcinoma; BRCA, Breast invasive carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, Cholangio carcinoma; COAD, Colon adenocarcinoma; DLBC, Lymphoid Neoplasm Diffuse Large B-cell Lymphoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and Neck squamous cell carcinoma; KICH, Kidney Chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LAML, Acute Myeloid Leukemia; LGG, Brain Lower Grade Glioma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma; MESO, Mesothelioma; OV, Ovarian serous cystadenocarcinoma; PAAD, Pancreatic
Declarations

Ethics approval and consent to participate

The study was approved by the First Affiliated Hospital of Nanchang University Ethics Committee, Nanchang, China (No.126), and all patients who underwent hepatectomy in this study signed tissue sample consent for clinical research.

Consent for publication

Not applicable.

Availability of data and materials

The data sets during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no conflict of interest.

Authors’ contributions

D.J. and JP.X. initiated and designed the work and prepared the manuscript. L.L., SS.H., YY.Y. performed the experiments. L.L., C.J., XJ.X., and JH.L. contributed to the acquisition of patients and tissues specimens and to the analysis and interpretation of data. All authors read and approved the final manuscript.

Funding

This work was supported in part by grants from the National Natural Science Foundation of China (grant number: 81860427, 81760432, 81660402 and 81660405), the JiangXi Province General Project (grant number: 20164BCD40097, 20171BBG70121 and 2017BBH80027), the Youth Scientific Funds-Youth Fund Project (grant number: 2018ACB21037 and 20171BAB215041), the JiangXi Province Education Fund Project (grant number: 700653002), the department of health of JiangXi Province Project (grant number: 20181041), the JiangXi Province Postgraduate Special Innovation Fund (grant number: YC2019-B034).

Author details
References

1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010 Aug;19(8):1893-907.

2. Matsueda S, Graham DY. Immunotherapy in gastric cancer. World journal of gastroenterology. 2014 Feb 21;20(7):1657-66.

3. Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Sep;23 Suppl 8(Suppl 8):viii6-9.

4. Zarour HM. Reversing T-cell Dysfunction and Exhaustion in Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Apr 15;22(8):1856-64.

5. Ling Z, Shao L, Liu X, Cheng Y, Yan C, Mei Y, et al. Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study. Frontiers in immunology. 2019;10:533.

6. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014 Jul 17;41(1):49-61.

7. Ngambenjawong C, Gustafson HH, Pun SH. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Advanced drug delivery reviews. 2017 May 15;114:206-21.

8. Zhou L, Xu L, Chen L, Fu Q, Liu Z, Chang Y, et al. Tumor-infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer. Oncoimmunology. 2017;6(4):e1293211.

9. Zhang H, Liu H, Shen Z, Lin C, Wang X, Qin J, et al. Tumor-infiltrating Neutrophils is Prognostic and Predictive for Postoperative Adjuvant Chemotherapy Benefit in Patients With Gastric Cancer. Annals of surgery. 2018 Feb;267(2):311-18.

10. Tanaka M, Ozaki S, Osakada F, Mori K, Okubo M, Nakao K. Cloning of follistatin-related protein as a novel autoantigen in systemic rheumatic diseases. International immunology. 1998 Sep;10(9):1305-14.

11. Le Luduec JB, Condamine T, Louvet C, Thebault P, Heslan JM, Heslan M, et al. An immunomodulatory role for follistatin-like 1 in heart allograft transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2008 Nov;8(11):2297-306.
12. An J, Wang L, Zhao Y, Hao Q, Zhang Y, Zhang J, et al. Effects of FSTL1 on cell proliferation in breast cancer cell line MDAMB231 and its brain metastatic variant MDAMB231BR. Oncology reports. 2017 Nov;38(5):3001-10.

13. Liu Y, Tan X, Liu W, Chen X, Hou X, Shen D, et al. Follistatin-like protein 1 plays a tumor suppressor role in clear-cell renal cell carcinoma. Chin J Cancer. 2018 Jan 22;37(1):2.

14. Gu C, Wang X, Long T, Wang X, Zhong Y, Ma Y, et al. FSTL1 interacts with VIM and promotes colorectal cancer metastasis via activating the focal adhesion signalling pathway. Cell Death Dis. 2018 May 29;9(6):654.

15. Lau MC, Ng KY, Wong TL, Tong M, Lee TK, Ming XY, et al. FSTL1 Promotes Metastasis and Chemoresistance in Esophageal Squamous Cell Carcinoma through NFkappaB-BMP Signaling Cross-talk. Cancer research. 2017 Nov 1;77(21):5886-99.

16. Yang W, Wu Y, Wang C, Liu Z, Xu M, Zheng X. FSTL1 contributes to tumor progression via attenuating apoptosis in a AKT/GSK-3beta - dependent manner in hepatocellular carcinoma. Cancer biomarkers : section A of Disease markers. 2017 Jul 19;20(1):75-85.

17. Kudo-Saito C. FSTL1 promotes bone metastasis by causing immune dysfunction. Oncoimmunology. 2013 Nov 1;2(11):e26528.

18. Kudo-Saito C, Ishida A, Shouya Y, Teramoto K, Igarashi T, Kon R, et al. Blocking the FSTL1-DIP2A Axis Improves Anti-tumor Immunity. Cell reports. 2018 Aug 14;24(7):1790-801.

19. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007 Feb;9(2):166-80.

20. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer research. 2017 Nov 1;77(21):e108-e10.

21. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic acids research. 2017 Jul 3;45(W1):W98-W102.

22. Nagy A, Lanczky A, Menyhart O, Gyorffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Scientific reports. 2018 Jun 15;8(1):9227.

23. Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome biology. 2016 Aug 22;17(1):174.

24. Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013 Jan 16;14:7.

25. Liberzon A, Birger C, Thorvalsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell systems. 2015 Dec 23;1(6):417-25.

26. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015 May;12(5):453-7.

27. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic acids research. 2009 Jan;37(1):1-13.
28. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.

29. Fang Z, Zhang L, Liao Q, Wang Y, Yu F, Feng M, et al. Regulation of TRIM24 by miR-511 modulates cell proliferation in gastric cancer. Journal of experimental & clinical cancer research : CR. 2017 Jan 23;36(1):17.

30. Chen X, Leung SY, Yuen ST, Chu KM, Ji J, Li R, et al. Variation in gene expression patterns in human gastric cancers. Mol Biol Cell. 2003 Aug;14(8):3208-15.

31. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010 Feb 25;29(8):1093-102.

32. Zhang D, He W, Wu C, Tan Y, He Y, Xu B, et al. Scoring System for Tumor-Infiltrating Lymphocytes and Its Prognostic Value for Gastric Cancer. Frontiers in immunology. 2019;10:71.

33. Sherman-Baust CA, Weeraratna AT, Rangel LB, Pizer ES, Cho KR, Schwartz DR, et al. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer cell. 2003 Apr;3(4):377-86.

34. Qiu S, Deng L, Liao X, Nie L, Qi F, Jin K, et al. Tumor-associated macrophages promote bladder tumor growth through PI3K/AKT signal induced by collagen. Cancer Sci. 2019 Jul;110(7):2110-18.

35. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in immunology. 2002 Nov;23(11):549-55.

36. Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol. 2017 Feb 28;10(1):58.

37. Kudo-Saito C, Fuwa T, Murakami K, Kawakami Y. Targeting FSTL1 prevents tumor bone metastasis and consequent immune dysfunction. Cancer research. 2013 Oct 15;73(20):6185-93.

38. Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nature reviews Immunology. 2017 Sep;17(9):559-72.

39. Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nature reviews Cancer. 2015 Jul;15(7):409-25.

40. Sun Y. Tumor microenvironment and cancer therapy resistance. Cancer letters. 2016 Sep 28;380(1):205-15.

41. Yaacoub K, Pedex R, Tarte K, Guillaumeux T. Role of the tumor microenvironment in regulating apoptosis and cancer progression. Cancer letters. 2016 Aug 10;378(2):150-9.

42. Fridman WH, Galon J, Dieu-Nosjean MC, Cremer I, Fisson S, Damotte D, et al. Immune infiltration in human cancer: prognostic significance and disease control. Current topics in microbiology and immunology. 2011;344:1-24.

43. Locati M, Mantovani A, Sica A. Macrophage activation and polarization as an adaptive component of innate immunity. Advances in immunology. 2013;120:163-84.
44. Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, et al. Macrophage plasticity, polarization, and function in health and disease. Journal of cellular physiology. 2018 Sep;233(9):6425-40.
45. Komohara Y, Fujiwara Y, Ohnishi K, Takeya M. Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy. Advanced drug delivery reviews. 2016 Apr 1;99(Pt B):180-85.
46. Murray PJ. Macrophage Polarization. Annual review of physiology. 2017 Feb 10;79:541-66.
47. Gardner A, Ruffell B. Dendritic Cells and Cancer Immunity. Trends in immunology. 2016 Dec;37(12):855-65.
48. Marshall EA, Ng KW, Kung SH, Conway EM, Martinez VD, Halvorsen EC, et al. Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis. Molecular cancer. 2016 Oct 27;15(1):67.
49. Tang M, Diao J, Cattral MS. Molecular mechanisms involved in dendritic cell dysfunction in cancer. Cellular and molecular life sciences : CMLS. 2017 Mar;74(5):761-76.
50. Chen LJ, Zheng X, Shen YP, Zhu YB, Li Q, Chen J, et al. Higher numbers of T-bet(+) intratumoral lymphoid cells correlate with better survival in gastric cancer. Cancer Immunol Immunother. 2013 Mar;62(3):553-61.
51. Li Q, Li Q, Chen J, Liu Y, Zhao X, Tan B, et al. Prevalence of Th17 and Treg cells in gastric cancer patients and its correlation with clinical parameters. Oncology reports. 2013 Sep;30(3):1215-22.
52. Chen W, Konkel JE. Development of thymic Foxp3(+) regulatory T cells: TGF-beta matters. Eur J Immunol. 2015 Apr;45(4):958-65.
53. Perrone G, Ruffini PA, Catalano V, Spino C, Santini D, Muretto P, et al. Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. European journal of cancer. 2008 Sep;44(13):1875-82.
54. Chi LJ, Lu HT, Li GL, Wang XM, Su Y, Xu WH, et al. Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma. Clin Exp Immunol. 2010 Sep;161(3):480-9.
55. Mempel TR, Pittet MJ, Khazaie K, Weninger W, Weissleder R, von Boehmer H, et al. Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity. 2006 Jul;25(1):129-41.
56. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009 Jan;10(1):29-37.
57. Fuertes Marraco SA, Neubert NJ, Verdeil G, Speiser DE. Inhibitory Receptors Beyond T Cell Exhaustion. Frontiers in immunology. 2015;6:310.
58. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nature reviews Immunology. 2015 Aug;15(8):486-99.
59. Dong Y, Geng Y, Li L, Li X, Yan X, Fang Y, et al. Blocking follistatin-like 1 attenuates bleomycin-induced pulmonary fibrosis in mice. J Exp Med. 2015 Feb 9;212(2):235-52.
60. Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, et al. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). Journal for immunotherapy of cancer. 2018 May 16;6(1):39.

61. Xia L, Liu Y, Wang Y. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Oncologist. 2019 Feb;24(Suppl 1):S31-S41.

Tables
Table 1.
Correlation of FSTL1 mRNA expression and clinical prognosis in GC with different clinicopathological factors by Kaplan-Meier plotter.

| Clinicopathological characteristics | Overall survival (N=882) |  | Progression-free survival (N=646) |  |
|-------------------------------------|-------------------------|----------------|---------------------------------|----------------|
|                                     | N | Hazard ratio | p-value | N | Hazard ratio | p-value |
| SEX                                 |   |             |         |   |             |         |
| Female                              | 236 | 1.89 (1.33-2.7) | **0.00035** | 201 | 1.97 (1.35-2.87) | **0.00036** |
| Male                                | 545 | 1.62 (1.31-2.01) | **7.90E-06** | 438 | 1.6 (1.26-2.03) | **9.20E-05** |
| STAGE                               |   |             |         |   |             |         |
| I                                   | 67 | 1.87 (0.69-5.07) | 0.21 | 60 | 0.47 (0.14-1.57) | 0.21 |
| II                                  | 140 | 1.71 (0.94-3.12) | 0.075 | 131 | 1.6 (0.82-3.12) | 0.17 |
| III                                 | 305 | 1.75 (1.31-2.34) | **0.00012** | 186 | 1.94 (1.34-2.81) | **0.00036** |
| IV                                  | 148 | 1.89 (1.28-2.81) | **0.0013** | 141 | 1.58 (1.05-2.37) | **0.026** |
| STAGE T                             |   |             |         |   |             |         |
| 2                                   | 241 | 2.14 (1.4-3.27) | **3.00E-04** | 239 | 1.85 (1.23-2.8) | **0.0029** |
| 3                                   | 204 | 1.72 (1.21-2.45) | **0.0022** | 204 | 1.6 (1.14-2.26) | **0.0063** |
| 4                                   | 38 | 3.17 (1.3-7.71) | **0.0074** | 39 | 4.67 (1.87-11.66) | **0.00035** |
| STAGE N                             |   |             |         |   |             |         |
| 0                                   | 74 | 1.75 (0.76-4.06) | 0.19 | 72 | 1.78 (0.78-4.08) | 0.17 |
| 1                                   | 225 | 2.34 (1.55-3.53) | **3.10E-05** | 222 | 2.35 (1.59-3.48) | **9.10E-06** |
| 2                                   | 121 | 1.91 (1.22-2.99) | **0.0043** | 125 | 2.06 (1.33-3.18) | **0.00088** |
| 3                                   | 76 | 2.4 (1.4-4.12) | **0.0011** | 76 | 1.96 (1.15-3.34) | **0.012** |
| 1+2+3                               | 422 | 2.15 (1.66-2.8) | **5.00E-09** | 423 | 2.19 (1.7-2.82) | **5.40E-10** |
| STAGE M |  |  |  |  |  |
|---------|---|---|---|---|---|
| 0       | 344 | 2.04 (1.55-2.7) | **2.90E-07** | 443 | 2.08 (1.59-2.71) | **3.30E-08** |
| 1       | 56  | 2.05 (1.12-3.75) | **0.018**     | 56  | 1.57 (0.85-2.88) | 0.14        |

| LAUREN CLASSIFICATION |  |  |  |  |  |
|-----------------------|---|---|---|---|---|
| Intestinal            | 320| 2.32 (1.69-3.19) | **1.00E-07** | 263 | 2.01 (1.39-2.89) | **0.00014** |
| Diffuse               | 241| 2.05 (1.45-2.89) | **3.50E-05** | 231 | 2.07 (1.46-2.93) | **2.60E-05** |
| Mix                   | 32 | 2.29 (0.82-6.35) | 0.1           | 28  | 2.71 (0.76-9.64) | 0.11        |

| DIFFERENTIATIONN |  |  |  |  |  |
|------------------|---|---|---|---|---|
| Poor             | 165| 1.37 (0.92-2.05) | 0.12          | 121 | 1.42 (0.9-2.25)  | 0.13        |
| Moderate         | 67 | 1.95 (0.99-3.86) | 0.051         | 67  | 2.32 (1.19-4.52) | **0.011**   |
| Well             | 32 | 13.34 (3.03-58.81)| **1.80E-05** | *   | *                  | *           |

| HER2 STATUS |  |  |  |  |  |
|-------------|---|---|---|---|---|
| Negative    | 532| 1.63 (1.3-2.04) | **1.70E-05** | 408 | 1.75 (1.35-2.27) | **1.50E-05** |
| Positive    | 344| 1.67 (1.27-2.19) | **0.00019**  | 233 | 1.75 (1.2-2.55)  | **0.0034**  |

*, Sample number too low for meaningful analysis; FSTL1, follistatin-like 1; GC, gastric cancer.
Table 2. The association of FSTL1 expression level with clinicopathological characteristics.

| Variables                      | Number | FSTL1 expression | p-value |
|--------------------------------|--------|------------------|---------|
|                                |        | Negative | Positive |         |
| Ages                           |        |           |          |         |
| ≤58                            | 116    | 64       | 52       | 0.48    |
| >58                            | 124    | 74       | 50       |         |
| Gender                         |        |           |          |         |
| Male                           | 164    | 92       | 72       | 0.519   |
| Female                         | 76     | 46       | 30       |         |
| Tumor Size                     |        |           |          |         |
| ≤4cm                           | 144    | 100      | 44       | <0.001  |
| ≥4cm                           | 96     | 38       | 58       |         |
| Depth of invasion              |        |           |          |         |
| T1/T2                          | 84     | 43       | 41       | 0.147   |
| T3/T4                          | 156    | 95       | 61       |         |
| Lymph node metastasis          |        |           |          |         |
| Negative                       | 80     | 62       | 18       | <0.001  |
| Positive                       | 160    | 76       | 84       |         |
| TNM stage                      |        |           |          |         |
| I/II                           | 134    | 90       | 44       | 0.001   |
| III                            | 106    | 48       | 58       |         |
| Differentiation                |        |           |          |         |
| Low/undifferentiated           | 145    | 78       | 67       | 0.151   |
| High/moderate                  | 95     | 60       | 35       |         |
| Nerve invasion                 |        |           |          |         |
| Negative                       | 148    | 86       | 62       | 0.809   |
| Positive                       | 92     | 52       | 40       |         |
| Vascular invasion              |        |           |          |         |
| Variables                        | Univariate analyses | Multivariate analyses |
|---------------------------------|---------------------|-----------------------|
|                                 | HR (95% CI)         | p-value               |
| **Age** (≥ 57 vs. <57)          | 1.051 (0.748-1.494) | 0.754                 |
| **Gender** (Male vs. Female)    | 1.359 (0.948-1.948) | 0.095                 |
| **Tumor size** (≥4cm vs. ≤4cm)  | 2.045 (1.442-2.901) | <0.001                |
| **Depth of invasion** (T3/T4 vs. T1/T2) | 3.095 (1.947-4.922) | <0.001                |
| **Lymph node metastasis** (Positive vs. Negative) | 3.885 (2.497-6.044) | <0.001                |
| **TNM stage** (III vs. I/II)    | 6.978 (4.694-10.373)| <0.001                |
| **Differentiation** (Low/undifferentiated vs. High/moderate) | 0.898 (0.635-1.272) | 0.546                 |
| **Nerve invasion** (Positive vs. Negative) | 0.96 (0.671-1.375) | 0.825                 |
| **Vascular invasion** (Positive vs. Negative) | 1.678 (1.186-2.374) | 0.003                 |
| **FSTL1 expression** (Positive vs. Negative) | 3.041 (2.067-4.474) | <0.001                |

OS, overall survival; HR, hazard ratio; TNM, tumor-node-metastasis; HR, Hazard ratio.

TNM, tumor-node-metastasis.
### Table 4.
Correlation analysis between FSTL1 and related gene markers of immune cells

| Description       | Gene markers | None    |          |          |
|-------------------|--------------|---------|----------|----------|
|                   |              | Cor     | P        | Cor      | P        |
| CD8+ T cell       | CD8A         | 0.26    | 8.45E-08 | 0.218    | 1.83E-05 |
|                   | CD8B         | 0.146   | 2.86E-03 | 0.121    | 1.82E-02 |
| T cell (general)  | CD3D         | 0.236   | 1.25E-06 | 0.179    | 4.58E-04 |
|                   | CD3E         | 0.26    | 8.57E-08 | 0.207    | 4.71E-05 |
|                   | CD2          | 0.305   | 2.82E-10 | 0.262    | 2.24E-07 |
| B cell            | CD19         | 0.265   | 4.36E-08 | 0.234    | 4.03E-06 |
|                   | CD79A        | 0.281   | 7.09E-09 | 0.232    | 4.95E-06 |
| Monocyte          | CD86         | 0.443   | 0.00E+00 | 0.408    | 1.16E-16 |
|                   | CD115 (CSF1R)| 0.555   | 0.00E+00 | 0.524    | 3.68E-28 |
| TAM               | CCL2         | 0.545   | 0.00E+00 | 0.52     | 1.36E-27 |
|                   | CD68         | 0.216   | 9.23E-06 | 0.178    | 5.08E-04 |
|                   | IL10         | 0.446   | 1.15E-21 | 0.425    | 4.09E-18 |
| M1 Macrophage     | INOS (NOS2)  | 0.007   | 8.88E-01 | -0.002   | 9.65E-01 |
|                   | IRF5         | 0.158   | 1.22E-03 | 0.129    | 1.17E-02 |
| M2 Macrophage     | CD163        | 0.492   | 0.00E+00 | 0.461    | 2.46E-21 |
|                   | VSIG4        | 0.53    | 0.00E+00 | 0.516    | 4.01E-27 |
|                   | MS4A4A       | 0.544   | 0.00E+00 | 0.521    | 8.69E-28 |
| Neutrophils       | CD66b (CEACAM8)| 0.013 | 7.85E-01 | 0.036    | 4.80E-01 |
|                   | CD11b (ITGAM)| 0.493   | 0.00E+00 | 0.472    | 2.04E-22 |
|                   | CCR7         | 0.362   | 2.81E-14 | 0.315    | 3.47E-10 |
| Natural killer cell| KIR2DL1     | 0.144   | 3.38E-03 | 0.131    | 1.09E-02 |
|                   | KIR2DL3      | 0.12    | 1.49E-02 | 0.098    | 5.60E-02 |
|                   | KIR2DL4      | -0.052  | 2.87E-01 | -0.097   | 5.89E-02 |
|                   | KIR3DL1      | 0.131   | 7.60E-03 | 0.112    | 2.86E-02 |
|                   | KIR3DL2      | 0.15    | 2.18E-03 | 0.129    | 1.23E-02 |
|                   | KIR3DL3      | -0.104  | 3.35E-02 | -0.092   | 7.23E-02 |
| Gene        | Log2 Fold Change (FPKM) | p-value | Log2 Fold Change (fold enrichment) | p-value |
|-------------|-------------------------|---------|----------------------------------|---------|
| KIR2DS4     | 0.054                   | 2.71E-01| 0.039                            | 4.45E-01|
| HLA-DPB1    | 0.278                   | 1.01E-08| 0.215                            | 2.40E-05|
| HLA-DQB1    | 0.137                   | 5.30E-03| 0.073                            | 1.58E-01|
| HLA-DRA     | 0.198                   | 5.01E-05| 0.142                            | 5.55E-03|
| HLA-DPA1    | 0.233                   | 1.67E-06| 0.178                            | 5.05E-04|
| BDCA-1 (CD1C)| 0.43                   | 4.41E-20| 0.4                               | 5.47E-16|
| BDCA-4 (NRP1)| 0.703                  | 0.00E+00| 0.682                            | 2.88E-53|
| CD11c (ITGAX)| 0.453                  | 0.00E+00| 0.418                            | 1.84E-17|
| T-bet (TBX21)| 0.235                  | 1.32E-06| 0.202                            | 7.32E-05|
| STAT4       | 0.368                   | 1.12E-14| 0.337                            | 1.73E-11|
| STAT1       | -0.018                  | 7.18E-01| -0.044                           | 3.95E-01|
| IFN-γ (IFNG) | -0.012                 | 8.09E-01| -0.038                           | 4.61E-01|
| TNF-α (TNF) | 0.116                   | 1.78E-02| 0.069                            | 1.82E-01|
| GATA3       | 0.309                   | 1.66E-10| 0.287                            | 1.27E-08|
| STAT6       | 0.052                   | 2.86E-01| 0.047                            | 3.59E-01|
| STAT5A      | 0.362                   | 3.79E-14| 0.343                            | 6.92E-12|
| IL13        | 0.13                    | 8.14E-03| 0.149                            | 3.56E-03|
| BCL6        | 0.447                   | 0.00E+00| 0.412                            | 6.29E-17|
| IL21        | 0.1                     | 4.19E-02| 0.082                            | 1.13E-01|
| STAT3       | 0.402                   | 0.00E+00| 0.38                             | 1.96E-14|
| IL17A       | -0.153                  | 1.76E-03| -0.17                            | 8.82E-04|
| FOXP3       | 0.273                   | 1.84E-08| 0.229                            | 6.89E-06|
| CCR8        | 0.395                   | 5.70E-17| 0.379                            | 2.26E-14|
| STAT5B      | 0.542                   | 0.00E+00| 0.533                            | 3.02E-29|
| TGFβ (TGFB1)| 0.565                   | 0.00E+00| 0.539                            | 6.66E-30|
| PD-1 (PDCD1)| 0.147                   | 2.78E-03| 0.104                            | 4.30E-02|
| CTLA4       | 0.157                   | 1.35E-03| 0.117                            | 2.23E-02|
| LAG3        | 0.121                   | 1.39E-02| 0.079                            | 1.26E-01|
| TIM-3 (HAVCR2)| 0.427                 | 0.00E+00| 0.399                            | 7.03E-16|
|          | GZMB  | 0.056 | 2.54E-01 | -0.004 | 9.36E-01 |
|----------|-------|-------|----------|--------|----------|

TAM, tumor-associated macrophage; Th, T helper cell; Tfh, Follicular helper T cell; Treg, regulatory T cell; Cor, R value of Spearman's correlation; None, correlation without adjustment. Purity, correlation adjusted by purity.